ADMA Biologics Inc (ADMA): Price and Financial Metrics

ADMA Biologics Inc (ADMA): $5.98

0.04 (-0.66%)

POWR Rating

Component Grades

Momentum

C

Stability

D

Sentiment

Quality

C

Add ADMA to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#86 of 363

in industry

ADMA Price/Volume Stats

Current price $5.98 52-week high $6.76
Prev. close $6.02 52-week low $3.06
Day low $5.94 Volume 1,815,200
Day high $6.21 Avg. volume 2,670,350
50-day MA $5.85 Dividend yield N/A
200-day MA $4.42 Market Cap 1.36B

ADMA Stock Price Chart Interactive Chart >


ADMA Biologics Inc (ADMA) Company Bio


ADMA Biologics, Inc. develops, manufactures, and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The company was founded in 2004 and is based in Ramsey, New Jersey.


ADMA Latest News Stream


Event/Time News Detail
Loading, please wait...

ADMA Latest Social Stream


Loading social stream, please wait...

View Full ADMA Social Stream

Latest ADMA News From Around the Web

Below are the latest news stories about ADMA BIOLOGICS INC that investors may wish to consider to help them evaluate ADMA as an investment opportunity.

Cytokinetics (CYTK) Up 83% as Cardiomyopathy Drug Meets Goals

Cytokinetics (CYTK) reports positive results from its pivotal late-stage study of aficamten in symptomatic obstructive hypertrophic cardiomyopathy patients. The stock rallies 83% in response.

Yahoo | December 28, 2023

Milestone Pharma (MIST) Down on Regulatory Update for Etripamil

Milestone Pharma (MIST) plunges 31% following an RTF letter from the FDA due to insufficient data to begin a substantive review of the regulatory filing for etripamil nasal spray to treat PSVT.

Yahoo | December 27, 2023

Merck (MRK) & Daiichi Sankyo's Lung Cancer ADC Gets Priority Tag

Merck (MRK) and Daiichi Sankyo's regulatory filing for HER3-DXd gets the FDA's priority review grant for the treatment of adult patients with lung cancer. A final decision is expected on Jun 26, 2024.

Yahoo | December 26, 2023

Wall Street Bulls Look Optimistic About Adma Biologics (ADMA): Should You Buy?

According to the average brokerage recommendation (ABR), one should invest in Adma Biologics (ADMA). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?

Yahoo | December 26, 2023

Should You Buy Adma Biologics (ADMA) After Golden Cross?

Is it a good or bad thing when a stock experiences a golden cross technical event?

Yahoo | December 25, 2023

Read More 'ADMA' Stories Here

ADMA Price Returns

1-mo -0.17%
3-mo 21.30%
6-mo 89.84%
1-year 79.04%
3-year 262.42%
5-year 29.44%
YTD 32.30%
2023 16.49%
2022 175.18%
2021 -27.69%
2020 -51.25%
2019 67.36%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!